Multicenter, open-label phase II study to evaluate the safety and efficacy of the trifunctional bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) in patients with gastric adenocarcinoma after neoadjuvant chemotherapy and intended curative resection.

Trial Profile

Multicenter, open-label phase II study to evaluate the safety and efficacy of the trifunctional bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) in patients with gastric adenocarcinoma after neoadjuvant chemotherapy and intended curative resection.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2013

At a glance

  • Drugs Catumaxomab (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Nov 2013 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently' (last verified Feb 2010).
    • 02 Oct 2012 Planned end date changed from 1 Jul 2011 to 1 Jul 2013 as reported by ClincialTrials.gov.
    • 13 Jun 2011 Results from a trial in gastric cancer presented at ASCO-2011. Could be this one, but not certain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top